DIABETIC ANGIOPATHY-RELATED CHRONIC LIMB-THREATENING ISCHEMIA: REVASCULARIZATION STRATEGIES AND DUAL ANTITHROMBOTIC THERAPY

IRAKLI POPKHADZE; TEIMURAZ MOSIAVA; TEONA LAZISHVILI; MANANA GOBEJISHVILI; DAVIT ABRAMISHVILI

doi:10.52340/jecm.2026.02.06

Authors

IRAKLI POPKHADZE Tbilisi Heart Center
TEIMURAZ MOSIAVA National Center of Surgery; Tbilisi, Georgia
TEONA LAZISHVILI Tbilisi Heart Center
MANANA GOBEJISHVILI Tbilisi Heart Center
DAVIT ABRAMISHVILI Tbilisi Heart Center

DOI:

https://doi.org/10.52340/jecm.2026.02.06

Keywords:

Diabetic, angiopathy, limb ischemia, revascularization, dual antithrombotic Therapy

Abstract

Diabetic angiopathy is a main complication of diabetes mellitus and a leading cause of chronic limb-threatening ischemia (CLTI). Patients with diabetes have higher risk for aggressive peripheral arterial disease, which is characterized by distal, multilevel arterial involvement, impaired wound healing, high risk of thrombosis and limb loss. Despite importance of peripheral revascularization in limb saving process, optimal post-revascularization antithrombotic therapy has a big role for prevention of complications, particularly in diabetic populations.

Downloads

Download data is not yet available.

References

Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2023;58(1S):S1–S109.

Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2024;45(Suppl S):S5–S67.

Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. Circulation. 2024;135(12):e726–e779.

Fowkes FGR, Aboyans V, Fowkes FJI, et al. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2024;14(3):156–170.

Beckman JA, Creager MA. Vascular complications of diabetes. Circ Res. 2025;118(11):1771–1785.

Brownlee M. The pathobiology of diabetic complications: a unifying mechanism.Diabetes.2025;54(6):1615-25

Jude EB, Oyibo SO, Chalmers N, Boulton AJM. Peripheral arterial disease in diabetic and nondiabetic patients. Diabetes Care. 2024;24(8):1433–1437.

Hinchliffe RJ, Forsythe RO, et al. Guidelines on diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers and diabetes. EurJVascEndovasc Surg. 2024;60(3):e1–e36.

Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2024;376(24):2367–2375.

Farber A, Menard MT, Conte MS, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med. 2025;387(25):2305–2316.

Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2025;382(21):1994–2004.

Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2022;379(14):1319–1330.

Hiatt WR, Fowkes FGR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376(1):32–40.

Capodanno D, Angiolillo DJ. Antithrombotic therapy for peripheral artery disease. J Am Coll Cardiol. 2023;75(6):498–510.

Hess CN, Norgren L, Ansel GM, et al. A structured review of antithrombotic therapy in peripheral artery disease. Eur Heart J. 2022;39(9):747–757.

Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases. Eur Heart J. 2019;39(9):763–816.

Makris GC, Lattimer CR, Geroulakos G. Angiosome-targeted revascularization in critical limb ischemia: a systematic review. J Endovasc Ther. 2024;21(5):657–668.

Paraskevas KI, Baker DM, Vrentzos GE, Mikhailidis DP. The role of inflammation and coagulation in diabetic vascular disease. Angiology. 2022;59(4):414–419.